Business Daily Media

Men's Weekly

.

Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea

  • Written by ACN Newswire - Press Releases

Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea

TOKYO, Sep 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku Corporation announced today that the companies have entered into an agreement for the marketing alliance in South Korea for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. Eisai and Seikagaku signed an agreement

Read more //?#

Australian Businesses Still Stuck in the AI Hype Cycle

Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

The Next Generation of Maritime Sustainable Solutions

As organizations globally seek innovative ways to improve sustainability and their impact on Earth, the American Waterways Operators (AWO), a lead...

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Sell by LayBy